Insmed (INSM) Misses Q4 EPS by 10c, Revenues Beat; Offers FY19 Revenue Outlook Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. BROS
3. ARM
4. FIS
5. QCOM
6. EXPE
7. CPAY
8. PAYC
9. SNAP
10. FSLY

Go back to Insmed (INSM) Misses Q4 EPS by 10c, Revenues Beat; Offers FY19 Revenue Outlook Above Consensus

Insmed Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

February 22, 2019 7:30 AM EST

BRIDGEWATER, N.J., Feb. 22, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2018 and provided a business update.

"2018 was a pivotal year for Insmed, with the U.S. approval and launch of ARIKAYCE® (amikacin liposome inhalation suspension), the first and only FDA-approved treatment for patients with refractory Mycobacterium avium complex (MAC) lung disease. We are very pleased with the strong... More